Originally characterized at the University of Florida by the Stephen ORahilly and Robert Kraft groups, the compound has been studied in preclinical research for body composition, adipose tissue lipolysis, glucose homeostasis, skeletal muscle aging, and metabolic disease endpoints
Patients come in for B12 injections on an as needed individualized schedule
Suffice it to say that a 2,000 g/day dose of cyanocobalamin is enough to ensure maximum B12 status in anyone without an extremely rare condition
A Phase 2 trial (NCT01311518) was designed to test RGN-352 in ~75 heart attack patients, but was placed on FDA clinical hold in 2011 due to manufacturing (GMP) compliance issues at the contract site not safety concerns with the drug itself
Summary of the findings The current article evaluated 13 studies, of which eight were randomized clinical trials comparing different administration routes of vitamin B12 in patients with vitamin B12 deficiency
